A clinical study on Maantha kudineer( internal) Maantha thailam( External) for Autism.

Phase II Non Randomized clinical study on Maantha sanni(Autism Spectrum Disorder) in children with the evaluation of siddha trail drug Maantha kudineer(internal)and Maantha thailam( External) - Nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/04/085726

Enrollment

Registered

2025-04-28

Start date

Unknown

Completion date

Unknown

Last updated

2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F988- Other specified behavioral and emotional disorders with onset usually occurring in childhood and adolescence

Interventions

Intervention1: Maantha kudineer(internal)Maantha thailam( external): Maantha kudineer 4-8 ml thrice a day for 48 days maantha thailam Thuvalai for 48 days Control Intervention1: Nil: Nil

Eligibility

Inclusion criteria

Inclusion criteria: Children have lack of eye contact Lack of response Repetitive or restricted behaviour Unawareness of natural urges Acquired speech or lost it Unusual sensitive to sensory stimuli

Exclusion criteria

Exclusion criteria: Severe and recurrent Seizures ADHD Cerebral palsy Infantile hemiplegia Congenital anomalies

Design outcomes

Primary

Measure	Time frame
Primary outcome is assessed by reduction of the clinical symptoms before and after treatmentTimepoint: 48 days	—

Secondary

Measure	Time frame
Secondary outcome is assessed by comparing the safety parameters before and after treatmentTimepoint: 48 days	—

Countries

India

Contacts

Public ContactDr R Thirumalaikumari

Government siddha medical college chennai

cspriya2004@gmail.com9445661808

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026